International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma Review uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Lung Neoplasms

abstract

  • This new classification strategy is based on a multidisciplinary approach to diagnosis of lung adenocarcinoma that incorporates clinical, molecular, radiologic, and surgical issues, but it is primarily based on histology. This classification is intended to support clinical practice, and research investigation and clinical trials. As EGFR mutation is a validated predictive marker for response and progression-free survival with EGFR tyrosine kinase inhibitors in advanced lung adenocarcinoma, we recommend that patients with advanced adenocarcinomas be tested for EGFR mutation. This has implications for strategic management of tissue, particularly for small biopsies and cytology samples, to maximize high-quality tissue available for molecular studies. Potential impact for tumor, node, and metastasis staging include adjustment of the size T factor according to only the invasive component (1) pathologically in invasive tumors with lepidic areas or (2) radiologically by measuring the solid component of part-solid nodules.

authors

publication date

  • February 2011

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4513953

Digital Object Identifier (DOI)

  • 10.1097/JTO.0b013e318206a221

PubMed ID

  • 21252716

Additional Document Info

start page

  • 244

end page

  • 85

volume

  • 6

number

  • 2